Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HAT1 | O14929 | 2/20 | 0.37 |
| ▸ | EP300 | Q09472 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15902481 | 0.85 | GABRA1 (0.45) | GABRA1GABRB2HAT1EP300LMNA | |
| SCHEMBL15901066 | 0.78 | HAT1 (0.47) | GABRA1GABRB2ALDH1A1SMN1; SMN2HAT1 | |
| SCHEMBL15902544 | 0.77 | LMNA (0.42) | ALDH1A1HAT1EP300LMNARAB9A | |
| SCHEMBL28604379 | 0.75 | HTR1A (0.34) | — | |
| SCHEMBL7733863 | 0.74 | MPO (0.56) | KMT2A | |
| SCHEMBL2403214 | 0.73 | MAPT (0.46) | GABRA1GABRB2MAPTMEN1KMT2A | |
| SCHEMBL15901976 | 0.72 | SLC6A2 (0.35) | GABRA1GABRB2ALDH1A1MAPTMEN1 | |
| SCHEMBL13894643 | 0.71 | GABRA1 (0.67) | GABRA1GABRB2ALDH1A1MEN1KMT2A | |
| SCHEMBL13894640 | 0.70 | KDM4E (0.51) | ALDH1A1SMN1; SMN2LMNAMAPTMEN1 | |
| SCHEMBL15902273 | 0.70 | GABRA1 (0.55) | GABRA1GABRB2ALDH1A1HAT1EP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012411-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-18 | — | — | US | disclosed |
| US-20220106321-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-04-07 | — | — | US | disclosed |
| US-11279704-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-03-22 | — | — | US | disclosed |
| EP-3617192-A1 | VIRAL REPLICATION INHIBITORS | Katholieke Universiteit Leuven K.U. Leuven R&D (BE) | 2020-03-04 | — | — | EP | disclosed |
| US-10550123-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2020-02-04 | — | — | US | disclosed |
| US-20190337954-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2019-11-07 | — | — | US | disclosed |
| EP-2760831-B1 | VIRAL REPLICATION INHIBITORS | UNIV LEUVEN KATH (BE) | 2019-08-07 | — | — | EP | disclosed |
| US-20140213586-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213586-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | GABRA1 4617/4885GABRB2 4748/4885ALDH1A1 4277/4885 |
| US-11279704-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | GABRA1 4617/4885GABRB2 4748/4885ALDH1A1 4277/4885 |
| US-20190337954-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | GABRA1 4617/4885GABRB2 4748/4885ALDH1A1 4277/4885 |
| US-10550123-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | GABRA1 4617/4885GABRB2 4748/4885ALDH1A1 4277/4885 |
| US-20220106321-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | GABRA1 4617/4885GABRB2 4748/4885ALDH1A1 4277/4885 |
| US-12012411-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | GABRA1 4617/4885GABRB2 4748/4885ALDH1A1 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.